Tesamorelin vs CJC-1295: Two GHRH Analogues With Different Clinical Footprints

Tesamorelin and CJC-1295 (no DAC) are both synthetic GHRH analogues that activate GHRH-R and stimulate pulsatile GH release. They differ primarily in their clinical evidence base: tesamorelin is FDA-approved with Phase 3 RCT data, while CJC-1295 exists only as a research compound.

Tesamorelin: FDA-Approved Clinical Evidence

Tesamorelin (Egrifta, 44-amino acid GHRH analogue with trans-3-hexenoic acid N-terminal modification) has a half-life of ~30-40 minutes. FDA approval was for HIV-associated lipodystrophy — abnormal visceral fat accumulation in HIV patients on antiretroviral therapy.

Pivotal trial (Falutz J et al., *NEJM*, 2010, n=816):

• Trunk fat (DXA): tesamorelin 2 mg/day SC × 26 weeks → −15.2% vs +5.0% placebo (p<0.001)
• Trunk fat % of body fat: −2.6% tesamorelin vs +0.5% placebo
• Visceral adipose tissue (CT): significantly reduced
• IGF-1: raised to normal range (from below-normal baseline)

These results established tesamorelin as the most rigorously validated peptide for visceral fat reduction in any specific clinical population, with FDA-recognised indication.

CJC-1295 (No DAC): Research Compound With Pharmacological Evidence

CJC-1295 (no DAC) has four amino acid substitutions (positions 2, 8, 15, 27) providing DPP-IV resistance and ~30-minute half-life — essentially identical to tesamorelin's pharmacokinetics. GHRH-R binding affinity and downstream GH-releasing potency are also equivalent at equimolar doses.

The key published clinical evidence (Teichman SL et al., *JCEM*, 2006) studied CJC-1295 with DAC — not the no-DAC form — making direct clinical extrapolation imperfect. No randomised clinical trials of CJC-1295 without DAC have been published.

The Evidence Gap

From receptor pharmacology, tesamorelin and CJC-1295 (no DAC) are essentially equivalent GHRH-R agonists with similar half-lives. The enormous practical difference is the clinical evidence base:

• Tesamorelin: 2 Phase 3 RCTs, ~1000 patients, FDA-approved, published in NEJM
• CJC-1295 (no DAC): No published RCTs; pharmacokinetic data only

This gap does not imply inferior efficacy for CJC-1295 (no DAC) — it simply means tesamorelin's effects have been rigorously established and CJC-1295's have not, primarily because CJC-1295 has not undergone pharmaceutical clinical development.

Visceral Fat Selectivity

Tesamorelin preferentially reduces visceral (intra-abdominal) vs subcutaneous fat — consistent with GH's preferential lipolytic effect on visceral adipocytes, which express higher GH receptor density. CJC-1295, producing the same downstream GH pulses, would be expected to show the same selectivity.

Tesamorelin is FDA-approved for HIV-associated lipodystrophy. CJC-1295 is a research compound not approved for any indication.

<!-- deep-links-v1 -->

Supporting GH Secretagogue Research References

The tesamorelin-CJC-1295 comparison is anchored by a wider secretagogue literature. Mod GRF 1-29, the parent 29-amino acid sequence shared by CJC-1295 without DAC, is the most direct mechanistic comparator to tesamorelin. GHRP-6 and Hexarelin are frequently co-administered in GH pulse studies to demonstrate GHRH analogue synergy at the GHS-R1a level. Ghrelin and Somatostatin define the endogenous regulatory counterparts. Somatropin (rHGH), the direct GH-replacement reference, contextualizes all indirect stimulation approaches including both tesamorelin and CJC-1295.